In the FRISC-II trial (FRagmin and Fast Revascularisation during InStability in Coronary artery disease), IL-6 was shown to predict mortality in those presenting with mortality and those with elevated IL-6 were shown to exclusively have a mortality benefit from an early invasive strategy whereas those with normal levels did not. Here, IL6 is linked to coronary artery disorder.